文献速递临床试验与 GCP

丹麦无收缩功能降低心肌梗死后β受体阻滞剂治疗试验的设计与原理:随机对照试验研究方案

Design and rationale of the Danish trial of beta-blocker treatment after myocardial infarction without reduced ejection fraction: study protocol for a randomized controlled trial.
PubMed 文献 · Trials · 2020-05-23

DANBLOCK是一项前瞻性、随机、对照、开放标签、非盲终点临床试验,旨在评估无左心室射血分数降低或心力衰竭的心肌梗死后患者使用β受体阻滞剂的疗效。计划随机分配3570例患者,在指数心肌梗死后14天内分组,随访至少2年。主要终点为全因死亡、再发心肌梗死、急性失代偿性心力衰竭、不稳定型心绞痛或卒中的复合终点。

要点

  • DANBLOCK试验针对无心力衰竭和左心室射血分数降低的心肌梗死后患者。
  • 计划随机分配3570例患者,随访至少2年,主要终点为复合心血管事件。
  • 结果将为未来临床指南提供重要科学证据。

核心结论

  • DANBLOCK试验旨在评估无左心室射血分数降低或心力衰竭的心肌梗死后患者长期使用β受体阻滞剂的疗效。
  • 该试验结果将为未来临床指南提供重要科学证据。

研究设计与样本

  • DANBLOCK是一项前瞻性、随机、对照、开放标签、非盲终点临床试验。
  • 计划随机分配3570例患者,在指数心肌梗死后14天内分组,随访至少2年。
  • 主要复合终点通过本地报告和 adjudicated 终点评估,并补充链接丹麦国家登记处。

关键数值与推荐

  • 主要终点为全因死亡、再发心肌梗死、急性失代偿性心力衰竭、不稳定型心绞痛或卒中的复合终点。
  • 次要终点包括患者报告结局和心血管死亡。
  • 将与挪威和瑞典的类似 ongoing 试验数据汇集进行个体患者数据 meta 分析。

临床怎么用

  • 该试验尚在进行中,结果未报告,暂不能指导临床实践。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Treatment with beta-blockers is currently recommended after myocardial infarction (MI). The evidence relies on trials conducted decades ago before implementation of revascularization and contemporary medical therapy or in trials enrolling patients with heart failure or reduced left ventricular ejection fraction (LVEF ≤ 40%). Accordingly, the impact of beta-blockers on mortality and morbidity following acute MI in patients without reduced LVEF or heart failure is unclear. METHODS/DESIGN: The Danish trial of beta-blocker treatment after myocardial infarction without reduced ejection fraction (DANBLOCK) is a prospective, randomized, controlled, open-label, non-blinded endpoint clinical trial designed to evaluate the efficacy of beta-blocker treatment in post-MI patients in the absence of reduced LVEF or heart failure. We will randomize 3570 patients will be randomized within 14 days of index MI to beta-blocker or control for a minimum of 2 years. The primary endpoint is a composite of all-cause mortality, recurrent MI, acute decompensated heart failure, unstable angina pectoris, or stroke. The primary composite endpoint will be assessed through locally reported and adjudicated endpoints supplemented by linkage to the Danish national registers. A number of secondary endpoints will be investigated including patient reported outcomes and cardiovascular mortality. Data from similar ongoing trials in Norway and Sweden will be pooled to perform an individual patient data meta-analysis. DISCUSSION: DANBLOCK is a randomized clinical trial investigating the effect of long-term beta-blocker therapy after myocardial infarction in patients without heart failure and reduced LVEF. Results from the trial will add important scientific evidence to inform future clinical guidelines. TRIAL REGISTRATION: Clinicaltrials.gov, NCT03778554. Registered on 19 December 2018. European Clinical Trials Database, 2018-002699-42, registered on 28 September 2018.

来源:Trials,查看原文。版权归原作者所有。

引用

  1. Kristensen AMD, Bovin A, Zwisler AD, et al. Design and rationale of the Danish trial of beta-blocker treatment after myocardial infarction without reduced ejection fraction: study protocol for a randomized controlled trial. Trials. 2020. PMID: 32446298. doi:10.1186/s13063-020-4214-6

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。